Literature DB >> 2405220

Paul Ehrlich as a commercial scientist and research administrator.

J Liebenau1.   

Abstract

Mesh：

Year:  1990        PMID： 2405220      PMCID： PMC1036001          DOI： 10.1017/s0025727300050274

Source DB:  PubMed          Journal:  Med Hist        ISSN： 0025-7273            Impact factor:   1.419


× No keyword cloud information.
  4 in total

1.  Industrial R & D in pharmaceutical firms in the early twentieth century.

Authors:  J Liebenau
Journal:  Bus Hist       Date:  1984

2.  Carl Voegtlin and the 'arsenic receptor' in chemotherapy.

Authors:  J Parascandola
Journal:  J Hist Med Allied Sci       Date:  1977-04       Impact factor: 2.088

3.  Public health and the production and use of diphtheria antitoxin in Philadelphia.

Authors:  J M Liebenau
Journal:  Bull Hist Med       Date:  1987       Impact factor: 1.314

4.  Styles in scientific explanation: Paul Ehrlich and Svante Arrhenius on Immunochemistry.

Authors:  L P Rubin
Journal:  J Hist Med Allied Sci       Date:  1980-10       Impact factor: 2.088
  4 in total
  5 in total

1.  Arrhenius vs. Ehrlich on immunochemistry: decisions about scientific progress in the context of the Nobel Prize.

Authors:  F Luttenberger
Journal:  Theor Med       Date:  1992-06

2.  Towards a hermeneutic of technomedical objects.

Authors:  Kjetil Rommetveit
Journal:  Theor Med Bioeth       Date:  2008-06-25

3.  The contribution of Paul Ehrlich to histochemistry: a tribute on the occasion of the centenary of his death.

Authors:  Igor Buchwalow; Werner Boecker; Markus Tiemann
Journal:  Virchows Arch       Date:  2014-10-31       Impact factor: 4.064

4.  Part of a scientific master plan? Paul Ehrlich and the origins of his receptor concept.

Authors:  Cay-Rüdiger Prüll
Journal:  Med Hist       Date:  2003-07       Impact factor: 1.419

Review 5.  Non-clinical studies required for new drug development - Part I: early in silico and in vitro studies, new target discovery and validation, proof of principles and robustness of animal studies.

Authors:  E L Andrade; A F Bento; J Cavalli; S K Oliveira; C S Freitas; R Marcon; R C Schwanke; J M Siqueira; J B Calixto
Journal:  Braz J Med Biol Res       Date:  2016-10-24       Impact factor: 2.590
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.